Eastman

Biocompatibility testing

Giant steps

Eastman Tritan™ copolyester addresses health and regulatory issues important to the infant care market. With this resin, Eastman took the first steps toward assessing the effects of products in contact with the body. Eastman used the introduction of Tritan EX401 and EX501 to lead the industry toward establishing biocompatibility testing protocols for the infant care market.

Tritan EX401 and EX501 are included in Eastman’s Customer Notification Procedure, which details the company’s policy for customer notification when significant changes are made in EX401 or EX501 sold in the infant care market. This procedure provides the industry with an added layer of confidence in the consistent quality and performance of Tritan.

You take health seriously.

Consumers are concerned about the safety of anything contacting their food, and the marketplace has spoken loudly regarding consumer products containing BPA. The infant care industry continues to work to eliminate BPA from products, including bottles, pacifiers, and breast pumps used worldwide by children 3 years old or younger. Some countries and geographic regions have legislation or pending legislation to eliminate BPA from all food contact applications, regardless of the age of the user.

Demonstrating safety should be a priority in the infant care market. When developing Tritan EX401 and EX501, Eastman sought standardized testing protocols that would ensure customer confidence in products that contact the body. Because no established testing protocol to assess such biocompatibility existed for the infant care market, Eastman took the initiative to establish such a protocol.

Eastman takes biocompatibility testing to a new level.

Eastman worked with Toxikon Corporation, a life sciences company specializing in compliance studies for product safety, to create a testing protocol that assessed the suitability of a product for contact with the body.

This testing was the first of its kind to be provided to manufacturers of infant care products. Eastman believes these protocols should be adopted industry-wide so that manufacturers of infant care products (even manufacturers who do not use Tritan EX401 and EX501) can provide the same high level of confidence to their customers.

 



A studied approach to consumer confidence

Eastman developed a protocol to evaluate the biocompatibility of materials intended for infant care applications based on steam sterilization. The following is a brief description of the testing, including the results achieved by Tritan EX401 and EX501. For additional information, visit us at eastman.com/tritan.

Cytotoxicity*

An agar diffusion test was conducted to evaluate the potential biological reactivity of mammalian cells in vitro. Mammalian cells were selected for this test because of their sensitivity to leachable cytotoxic substances.

Results: There was no biological reactivity observed at 48 hours postexposure. Under accepted guidelines, these results indicate that Tritan EX401 and EX501 are noncytotoxic.

Sensitization reactions*

A direct-contact Buehler sensitization test was conducted to evaluate the potential to produce skin sensitization in mammalian tissue in vivo. Topical application was selected because it represents a likely route of human exposure for infant care products.

Results: No skin reactions or overt signs of toxicity were detected. Tritan EX401 and EX501 are not considered a skin sensitizer.

Skin irritation responses*

A primary skin irritation test was conducted to evaluate the potential to produce primary dermal irritation after a single topical exposure. Dermal exposure was selected because it represents a likely route of human exposure for infant care products.

Results: There were no signs of erythema (redness) or edema (swelling) at any point during the observation period. Tritan EX401 and EX501 are considered negligible irritants.

For more information on the safety of Eastman Tritan™ copolyester, visit www.TritanSafe.com.

*All studies conducted in compliance with the current FDA 21 CFR, Part 58–Good Laboratory Practice for Nonclinical Laboratory Studies.

© 2019 Eastman Chemical Company or its subsidiaries. All rights reserved.
As used herein, ® denotes registered trademark status in the U.S. only.